Zacks Investment Research upgraded shares of GENVEC INC (GNVC) from UNDERPERFORM to NEUTRAL on November 27, 2012, with a target price of $1.30.
GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of the Company's product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. GenVec's lead product, TNFerade is currently in a pivotal Phase II/III study in locally advanced pancreatic cancer Phase II studies are in progress in rectal cancer and metastatic melanoma and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, seasonal and pandemic flu, and foot-and-mouth disease.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on GENVEC INC (GNVC),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment